Kremer J, Bingham C, Cappelli L, et al. Post-appoval comparative safety study of tofacitinib and biological DMARDS: five-year results from a US-based rheumatoid arthritis registry. EULAR 2019; Madrid: Abstract OP0028.
Cardiovasculair risico bij reumapatiënten behandeld met biologicals of tofacitinib
mrt 2018 | Arthritis psoriatica, JIA, RA, Spondyloartritis